Lexeo Therapeutics, Inc. Common Stock
General ticker "LXEO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $483.2M (TTM average)
Lexeo Therapeutics, Inc. Common Stock does not follow the US Stock Market performance with the rate: -0.1%.
Estimated limits based on current volatility of 3.0%: low 4.20$, high 4.46$
Factors to consider:
- Earnings expected soon, date: 2026-08-13 bmo
- Total employees count: 59 (-18.1%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Net losses, No approved products, Inability to raise capital, Clinical trial failure, Regulatory and compliance
- Current price 31.4% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.02$, 16.66$]
- 2026-12-31 to 2027-12-31 estimated range: [4.03$, 11.66$]
Financial Metrics affecting the LXEO estimates:
- Negative: with PPE of -4.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -17.91 <= 0.30
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Shareholder equity ratio, % of 91.80 > 63.79
- Positive: Interest expense per share per price, % of 0.02 <= 0.75
- Negative: -0.76 < Inventory ratio change, % of 0
Short-term LXEO quotes
Long-term LXEO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $68.51MM | $105.77MM | $109.26MM |
| Operating Income | $-68.51MM | $-105.77MM | $-109.26MM |
| Non-Operating Income | $2.12MM | $7.39MM | $9.52MM |
| Interest Expense | $0.20MM | $0.14MM | $0.10MM |
| R&D Expense | $53.13MM | $74.09MM | $63.80MM |
| Income(Loss) | $-66.39MM | $-98.38MM | $-99.74MM |
| Net Income(Loss)* | $-66.39MM | $-98.33MM | $-99.96MM |
| Stockholders Equity | $113.53MM | $116.84MM | $246.67MM |
| Assets | $139.81MM | $146.94MM | $268.69MM |
| Operating Cash Flow | $-59.50MM | $-81.15MM | $-98.56MM |
| Capital expenditure | $0.17MM | $0.48MM | $0.40MM |
| Investing Cash Flow | $-0.17MM | $-94.08MM | $-90.25MM |
| Financing Cash Flow | $103.79MM | $88.78MM | $216.79MM |
| Earnings Per Share** | $-2.49 | $-3.09 | $-1.86 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.